Granahan Investment Management LLC Sells 301,550 Shares of Xeris Biopharma Holdings, Inc. $XERS

Granahan Investment Management LLC trimmed its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 24.6% during the first quarter, Holdings Channel reports. The fund owned 921,854 shares of the company’s stock after selling 301,550 shares during the quarter. Granahan Investment Management LLC’s holdings in Xeris Biopharma were worth $5,347,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Cetera Investment Advisers grew its holdings in Xeris Biopharma by 3.9% during the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after purchasing an additional 1,735 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after buying an additional 1,820 shares during the period. Royal Bank of Canada grew its stake in Xeris Biopharma by 6.5% in the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after buying an additional 2,351 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in Xeris Biopharma by 17.7% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,070 shares of the company’s stock valued at $126,000 after buying an additional 2,420 shares during the last quarter. Finally, AlphaCentric Advisors LLC raised its holdings in Xeris Biopharma by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock worth $266,000 after acquiring an additional 2,494 shares during the period. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Trading Down 1.1%

Shares of Xeris Biopharma stock opened at $8.32 on Friday. Xeris Biopharma Holdings, Inc. has a 52-week low of $4.87 and a 52-week high of $10.08. The firm has a market capitalization of $1.44 billion, a PE ratio of 138.67 and a beta of 0.62. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The company’s fifty day moving average price is $7.30 and its two-hundred day moving average price is $6.76.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The company had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. On average, analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Insider Activity

In other news, insider Kevin Mcculloch sold 90,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $8.03, for a total value of $722,700.00. Following the completion of the sale, the insider directly owned 1,691,126 shares in the company, valued at approximately $13,579,741.78. This trade represents a 5.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 27,600 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00. Following the completion of the transaction, the insider directly owned 1,366,053 shares of the company’s stock, valued at approximately $11,638,771.56. This represents a 1.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 251,500 shares of company stock worth $1,846,457. 4.35% of the stock is currently owned by insiders.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.